Prime Medicine, Inc. (PRME) Stock Price & Analysis
Prime Medicine, Inc. (PRME) fell 4.46% to USD 3.54 as of September 8, 2026 at 18:32 UTC, according to Nexqual real-time market data.
PRME last closed at USD 3.7; the session ranged USD 3.41–3.65 on volume of 2,116,524 shares. Market capitalization is $641.17M, with a 52-week range of USD 2.67–6.94 (NGM). Source: Nexqual, September 8, 2026 at 18:32 UTC.
Key Statistics (as of September 8, 2026 at 18:32 UTC)
| Price | USD 3.54 |
|---|---|
| Change | ▼ 4.46% (down) |
| Previous Close | USD 3.7 |
| Open | USD 3.65 |
| Day Range | USD 3.41 – 3.65 |
| 52-Week Range | USD 2.67 – 6.94 |
| Volume | 2,116,524 shares |
| Market Cap | $641.17M |
| Exchange | NGM |
Technical Analysis (PRME)
Nexqual's technical model rates PRME "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 8, 2026 at 18:32 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.26 (neutral) |
| vs SMA50 | Above (USD 3.39) |
| MACD | 0.12 (positive) |
Analyst Ratings (PRME)
Wall Street analysts rate PRME "Strong Buy" based on 11 analysts, with a mean price target of USD 7.11 (range USD 4.25–11), per Nexqual as of September 8, 2026 at 18:32 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 7.11 |
| High Target | USD 11 |
| Low Target | USD 4.25 |
| Buy / Hold / Sell | 11 / 3 / 0 |
Earnings (PRME)
| Next Earnings Date | 2026-11-06 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $2.42M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.24 vs est -0.26 ▲ beat |
| 2026-03-31 | USD -0.28 vs est -0.25 ▼ miss |
| 2025-12-31 | USD -0.24 vs est -0.26 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.25 ▼ miss |
Source: Nexqual, September 8, 2026 at 18:32 UTC.
Financials & Fundamentals (PRME)
| Total Revenue | $4.07M |
|---|---|
| Revenue Growth (YoY) | +3.50% |
| Gross Margin | +0.00% |
| Operating Margin | -3750.87% |
| Profit Margin | +0.00% |
| ROE | -373.29% |
| Debt / Equity | 282.54 |
| Current Ratio | 3.06 |
| Total Cash | $95.07M |
| Total Debt | $112.48M |
| Free Cash Flow | $-75.78M |
Source: Nexqual, September 8, 2026 at 18:32 UTC.
Financial Health Score (PRME)
Nexqual rates Prime Medicine, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 18:32 UTC.
| Growth | Strong — Revenue +55% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $95M cash vs $112M debt |
| Cash Flow | Weak — FCF negative: -$76M, burning cash |
| Efficiency | Critical — ROE -373%, ROA -46.5% |
Ownership (PRME)
| Insider Ownership | +23.66% |
|---|---|
| Institutional Ownership | +71.20% |
| Shares Outstanding | 181.38M |
| Float | 112.25M |
| Short % of Float | +24.68% |
Source: Nexqual, September 8, 2026 at 18:32 UTC.
Leadership (PRME)
Prime Medicine, Inc. is led by Allan Reine (age 50), CEO & Director, per Nexqual as of September 8, 2026 at 18:32 UTC.
| CEO & Director | Allan Reine (age 50) |
|---|---|
| Chief Financial Officer | Svetlana Makhni (age 41) |
Major Backers & Investors (PRME)
Notable institutional backers of Prime Medicine, Inc. include ARK Invest, Alphabet Inc., T. Rowe Price, according to Nexqual as of September 8, 2026 at 18:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 10.11% |
| Alphabet Inc. | 9.13% |
| T. Rowe Price | 4.31% |
| Balyasny Asset Management LP | 2.19% |
| Goldman Sachs | 1.89% |
| Casdin Capital, LLC | 1.75% |
| Woodline Partners LP | 1.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 7.06% |
| BlackRock | 6.67% |
| Vanguard Group | 4.93% |
Source: Nexqual, September 8, 2026 at 18:32 UTC.
From Prime Medicine, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Prime Editing Platform Architecture The core components of our platform include the Prime Editor enzyme, pegRNAs, and delivery vehicles.
- We expect our focus on liver-directed in vivo editing, combined with the modularity of our platform, will allow us to build a pipeline with breadth and depth while maintaining operational efficiency and disciplined capital deployment.
- Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks.
- We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies.
Partnerships
- We received a $55.0 million upfront payment under the BMS Collaboration Agreement and a $55.0 million equity investment under a Securities Purchase Agreement with BMS.
- Cystic Fibrosis Foundation 2024 Agreement In January 2024, we entered into an agreement with CFF, or the 2024 CFF Agreement, under which CFF agreed to provide up to $15.0 million, payable in multiple tranches, to support the development of Prime Editors for the 7 treatment of CF.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | USD 1.58 | ▲ 0.32% |
| SANA | Sana Biotechnology, Inc. | USD 3.56 | ▼ 9.31% |
| ABSI | Absci Corporation | USD 8.96 | ▲ 1.76% |
| BEAM | Beam Therapeutics Inc. | USD 26.74 | ▼ 9.23% |
| RLAY | Relay Therapeutics, Inc. | USD 18.88 | ▼ 0.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 18:32 UTC. This page is informational and not investment advice.